10-K: Notable Labs Reports 2023 Financial Results and Provides Business Update

Notable Labs, a clinical-stage platform therapeutics company, released its 2023 financial results and provided an update on its business, including the progress of its predictive precision medicine platform and clinical programs.

Summary

• Notable Labs, a clinical-stage platform therapeutics company, reported its financial results for the year ended December 31, 2023.
• The company is focused on developing predictive precision medicines for cancer patients using its proprietary PPMP platform.
• Notable's PPMP platform has demonstrated 83-100% predictive precision in clinical validation trials.
• The company is advancing two clinical-stage candidates for AML, Volasertib and Fosciclopirox, using its PPMP platform.
• Notable expects to initiate a Phase 2 trial for Volasertib in adult AML in the second quarter of 2024, with initial results expected in the fourth quarter of 2024.
• The company is co-developing Fosciclopirox with CicloMed for AML patients.
• Notable reported a net loss of $11.3 million for 2023, compared to a net loss of $14.4 million in 2022.
• Research and development expenses decreased to $4.7 million in 2023 from $7.8 million in 2022.
• General and administrative expenses increased to $10.1 million in 2023 from $5.2 million in 2022.
• The company had cash and cash equivalents of $8.2 million as of April 1, 2024, and expects to be able to finance operations through November 2024.
• Notable anticipates needing to raise additional capital to continue its operations.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the technology and clinical trial progress are promising, the financial losses and need for additional capital raise concerns. The company is still in the early stages of development and faces significant risks.

Positives

• The PPMP platform has demonstrated high predictive precision in clinical trials.
• Notable is advancing two clinical-stage candidates for AML.
• The company has a co-development partnership with CicloMed for Fosciclopirox.
• Research and development expenses decreased year-over-year.

Negatives

• The company reported a net loss of $11.3 million for 2023.
• General and administrative expenses increased significantly year-over-year.
• Notable expects to need to raise additional capital to continue operations.
• The company has a limited operating history and has not yet obtained regulatory approval for any product candidates.

Risks

• Notable has a limited operating history and may not be successful in its transition to a commercial company.
• The company has incurred significant losses since its inception and anticipates continuing to incur losses.
• Notable will need to raise additional capital, which may not be available on acceptable terms or at all.
• The company faces significant competition from other biopharmaceutical companies.
• Notables product candidates are in the early stages of clinical development and may not receive regulatory approval.
• Clinical trials may be delayed or terminated, and results may not be indicative of later-stage trials.
• The company may experience difficulties in patient enrollment for clinical trials.
• Notables drug candidates may cause undesirable side effects.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or failures.
• Notable may not be able to obtain or maintain intellectual property protection.
• The company may be subject to product liability claims.
• Cybersecurity risks and data breaches could negatively affect the business.
• The company may not be able to obtain adequate reimbursement for its products.
• The company is subject to extensive regulation by government authorities.
• The company may be subject to healthcare fraud and abuse laws.
• The company may be subject to data privacy and security regulations.
• The company may be subject to political, economic and military instability in Israel.

Future Outlook

Notable expects to initiate a Phase 2 trial for Volasertib in adult AML in the second quarter of 2024, with initial results expected in the fourth quarter of 2024. The company also anticipates needing to raise additional capital to continue its operations.

Management Comments

• Notable aims to be the leader in predictive precision medicine and revolutionize the way in which patients seek and receive treatments that are most likely to work best for them.
• Notable will leverage its PPMP with the goal to identify and select Volasertib-responsive patients prior to their treatment and enable Notable to potentially increase response rates and fast-track Volasertibs clinical development in this patient population.

Industry Context

The pharmaceutical industry is characterized by rapid evolution of technologies and intense competition. Notable faces competition from major pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. There are several PLK1 inhibitors in development, which could be competitive with Notables efforts.

Comparison to Industry Standards

• The company's PPMP platform has demonstrated a high predictive precision of 83-100% in clinical trials, which is a notable achievement compared to traditional precision medicine approaches that rely on genetic biomarkers.
• While there are no current FDA-approved PLK1 inhibitors, several companies are developing them, including Onvansertib (Cardiff Oncology, Inc.), GSK461364 (GSK, plc), rigosertib (Onconova Therapeutics, Inc.) and CY140 (Cyclacel Pharmaceuticals, Inc.).
• The company's approach of in-licensing assets that have shown clinical activity in a subset of patients and using PPMP to identify responders is a unique strategy compared to traditional drug development.
• The company's focus on improving patient outcomes for patients with the highest medical needs (e.g., response rates of 0-50% by current standard of care) is a differentiated approach compared to companies targeting broader patient populations.

Management Changes

Related Party Transactions

• In February 2023, Notable entered into a master service agreement with LifeSci Advisors for investor relations services, with an approximate monthly retainer of $20,000. Michael Rice, a director of Notable, is a principal of LifeSci Advisors.
• Approximately 64.9% of the financing from the sale of the Series C SAFEs was received from parties who are related to or affiliated with members of Notable Labs, Inc.'s former board of directors.
• Approximately 46.0% of the financing from the sale of the Series D SAFEs was received from parties who were related to or affiliated with members of Notable Labs, Inc.'s former board of directors.
• Approximately 34.3% of the Series D-2 Preferred Stock financing was committed from parties who are related to or affiliated with members of Notable Labs, Inc.'s former board of directors.

Stakeholder Impact

• Shareholders may experience dilution due to future equity offerings.
• Employees may be affected by potential changes in the company's operations and financial stability.
• Patients may benefit from the development of new predictive precision medicines.
• Third-party payors may be impacted by the pricing and reimbursement of Notables products.

Next Steps

• Notable plans to initiate a Phase 2 trial for Volasertib in adult AML in the second quarter of 2024.
• The company expects to deliver data from a Phase 2 dose optimization prelude targeting six patients in the fourth quarter of 2024.
• Notable plans to enroll the first PPMP-selected patient in the fourth quarter of 2024.
• The company will continue to use PPMP to identify additional assets for in-licensing.

Key Dates

Keywords

Predictive Precision Medicine, PPMP, AML, Volasertib, Fosciclopirox, Clinical Trials, Oncology, Drug Development, Biopharmaceutical, Therapeutics